Adalvo is pleased to announce a new collaboration with Eurofarma, a Brazilian-owned multinational pharmaceutical company that promotes access to health and quality of life with treatments at a fair price and profitable operations.
This collaboration is integral to Adalvo's commitment to expanding its presence in LATAM and improving patient access to essential medications through close collaboration with its partners.
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 100 countries and for over 110 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering highest quality differentiated products and services to our partners.
With headquarters in Malta, the company has additional offices in more than 16 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customized to our partners, and is designed to challenge the status quo: together, this helps our partners achieve their business goals.
We take pride in our ability to help its partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavors, driven by a deep-rooted passion to making a difference for partners.
The company’s purpose driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.
About Eurofarma Group
Founded in 1972, Eurofarma operates in the healthcare sector with the production and commercialization of products and services to improve people's quality of life. With a focus on shared value generation, it covers all major pharmaceutical segments, such as Prescription, Generics, OTC, Hospital, and Oncology. With broad coverage of therapeutic classes, the portfolio in the region comprises 2.8 thousand SKUs and serves 42 medical specialties.
Present in 22 countries, primarily in Latin America, Eurofarma also has operations in the USA and Africa. With more than 11 thousand employees, in 2022 it became a publicly traded company registered with the Brazilian Securities and Exchange Commission (CVM). It reported R$ 8 billion in net revenue, a growth of 13.3% compared to the previous year, with R$ 2 billion in EBITDA, an evolution of 20%. In R&D, investments in the year totaled more than R$ 590 million, equivalent to 7.4% of net revenue